Evidence for label-retaining tumour-initiating cells in human glioblastoma

Loic P. Deleyrolle, Angus Harding, Kathleen Cato, Florian A. Siebzehnrubl, Maryam Rahman, Hassan Azari, Sarah Olson, Brian Gabrielli, Geoffrey Osborne, Angelo Vescovi, Brent A. Reynolds

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Individual tumour cells display diverse functional behaviours in terms of proliferation rate, cell-cell interactions, metastatic potential and sensitivity to therapy. Moreover, sequencing studies have demonstrated surprising levels of genetic diversity between individual patient tumours of the same type. Tumour heterogeneity presents a significant therapeutic challenge as diverse cell types within a tumour can respond differently to therapies, and inter-patient heterogeneity may prevent the development of general treatments for cancer. One strategy that may help overcome tumour heterogeneity is the identification of tumour sub-populations that drive specific disease pathologies for the development of therapies targeting these clinically relevant sub-populations. Here, we have identified a dye-retaining brain tumour population that displays all the hallmarks of a tumour-initiating sub-population. Using a limiting dilution transplantation assay in immunocompromised mice, label-retaining brain tumour cells display elevated tumour-initiation properties relative to the bulk population. Importantly, tumours generated from these label-retaining cells exhibit all the pathological features of the primary disease. Together, these findings confirm dye-retaining brain tumour cells exhibit tumour-initiation ability and are therefore viable targets for the development of therapeutics targeting this sub-population.

Original languageEnglish
Pages (from-to)1331-1343
Number of pages13
JournalBrain
Volume134
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Neoplastic Stem Cells
Glioblastoma
Neoplasms
Brain Neoplasms
Population
Coloring Agents
Therapeutics
Aptitude
Cell Communication
Transplantation
Cell Proliferation
Pathology

Keywords

  • brain tumour
  • cancer stem cells
  • glioblastoma
  • label-retaining cells
  • tumour-initiating cells

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Deleyrolle, L. P., Harding, A., Cato, K., Siebzehnrubl, F. A., Rahman, M., Azari, H., ... Reynolds, B. A. (2011). Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain, 134(5), 1331-1343. https://doi.org/10.1093/brain/awr081

Evidence for label-retaining tumour-initiating cells in human glioblastoma. / Deleyrolle, Loic P.; Harding, Angus; Cato, Kathleen; Siebzehnrubl, Florian A.; Rahman, Maryam; Azari, Hassan; Olson, Sarah; Gabrielli, Brian; Osborne, Geoffrey; Vescovi, Angelo; Reynolds, Brent A.

In: Brain, Vol. 134, No. 5, 05.2011, p. 1331-1343.

Research output: Contribution to journalArticle

Deleyrolle, LP, Harding, A, Cato, K, Siebzehnrubl, FA, Rahman, M, Azari, H, Olson, S, Gabrielli, B, Osborne, G, Vescovi, A & Reynolds, BA 2011, 'Evidence for label-retaining tumour-initiating cells in human glioblastoma', Brain, vol. 134, no. 5, pp. 1331-1343. https://doi.org/10.1093/brain/awr081
Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H et al. Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain. 2011 May;134(5):1331-1343. https://doi.org/10.1093/brain/awr081
Deleyrolle, Loic P. ; Harding, Angus ; Cato, Kathleen ; Siebzehnrubl, Florian A. ; Rahman, Maryam ; Azari, Hassan ; Olson, Sarah ; Gabrielli, Brian ; Osborne, Geoffrey ; Vescovi, Angelo ; Reynolds, Brent A. / Evidence for label-retaining tumour-initiating cells in human glioblastoma. In: Brain. 2011 ; Vol. 134, No. 5. pp. 1331-1343.
@article{1345ee1a0c1748d48455b74350b05fcb,
title = "Evidence for label-retaining tumour-initiating cells in human glioblastoma",
abstract = "Individual tumour cells display diverse functional behaviours in terms of proliferation rate, cell-cell interactions, metastatic potential and sensitivity to therapy. Moreover, sequencing studies have demonstrated surprising levels of genetic diversity between individual patient tumours of the same type. Tumour heterogeneity presents a significant therapeutic challenge as diverse cell types within a tumour can respond differently to therapies, and inter-patient heterogeneity may prevent the development of general treatments for cancer. One strategy that may help overcome tumour heterogeneity is the identification of tumour sub-populations that drive specific disease pathologies for the development of therapies targeting these clinically relevant sub-populations. Here, we have identified a dye-retaining brain tumour population that displays all the hallmarks of a tumour-initiating sub-population. Using a limiting dilution transplantation assay in immunocompromised mice, label-retaining brain tumour cells display elevated tumour-initiation properties relative to the bulk population. Importantly, tumours generated from these label-retaining cells exhibit all the pathological features of the primary disease. Together, these findings confirm dye-retaining brain tumour cells exhibit tumour-initiation ability and are therefore viable targets for the development of therapeutics targeting this sub-population.",
keywords = "brain tumour, cancer stem cells, glioblastoma, label-retaining cells, tumour-initiating cells",
author = "Deleyrolle, {Loic P.} and Angus Harding and Kathleen Cato and Siebzehnrubl, {Florian A.} and Maryam Rahman and Hassan Azari and Sarah Olson and Brian Gabrielli and Geoffrey Osborne and Angelo Vescovi and Reynolds, {Brent A.}",
year = "2011",
month = "5",
doi = "10.1093/brain/awr081",
language = "English",
volume = "134",
pages = "1331--1343",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Evidence for label-retaining tumour-initiating cells in human glioblastoma

AU - Deleyrolle, Loic P.

AU - Harding, Angus

AU - Cato, Kathleen

AU - Siebzehnrubl, Florian A.

AU - Rahman, Maryam

AU - Azari, Hassan

AU - Olson, Sarah

AU - Gabrielli, Brian

AU - Osborne, Geoffrey

AU - Vescovi, Angelo

AU - Reynolds, Brent A.

PY - 2011/5

Y1 - 2011/5

N2 - Individual tumour cells display diverse functional behaviours in terms of proliferation rate, cell-cell interactions, metastatic potential and sensitivity to therapy. Moreover, sequencing studies have demonstrated surprising levels of genetic diversity between individual patient tumours of the same type. Tumour heterogeneity presents a significant therapeutic challenge as diverse cell types within a tumour can respond differently to therapies, and inter-patient heterogeneity may prevent the development of general treatments for cancer. One strategy that may help overcome tumour heterogeneity is the identification of tumour sub-populations that drive specific disease pathologies for the development of therapies targeting these clinically relevant sub-populations. Here, we have identified a dye-retaining brain tumour population that displays all the hallmarks of a tumour-initiating sub-population. Using a limiting dilution transplantation assay in immunocompromised mice, label-retaining brain tumour cells display elevated tumour-initiation properties relative to the bulk population. Importantly, tumours generated from these label-retaining cells exhibit all the pathological features of the primary disease. Together, these findings confirm dye-retaining brain tumour cells exhibit tumour-initiation ability and are therefore viable targets for the development of therapeutics targeting this sub-population.

AB - Individual tumour cells display diverse functional behaviours in terms of proliferation rate, cell-cell interactions, metastatic potential and sensitivity to therapy. Moreover, sequencing studies have demonstrated surprising levels of genetic diversity between individual patient tumours of the same type. Tumour heterogeneity presents a significant therapeutic challenge as diverse cell types within a tumour can respond differently to therapies, and inter-patient heterogeneity may prevent the development of general treatments for cancer. One strategy that may help overcome tumour heterogeneity is the identification of tumour sub-populations that drive specific disease pathologies for the development of therapies targeting these clinically relevant sub-populations. Here, we have identified a dye-retaining brain tumour population that displays all the hallmarks of a tumour-initiating sub-population. Using a limiting dilution transplantation assay in immunocompromised mice, label-retaining brain tumour cells display elevated tumour-initiation properties relative to the bulk population. Importantly, tumours generated from these label-retaining cells exhibit all the pathological features of the primary disease. Together, these findings confirm dye-retaining brain tumour cells exhibit tumour-initiation ability and are therefore viable targets for the development of therapeutics targeting this sub-population.

KW - brain tumour

KW - cancer stem cells

KW - glioblastoma

KW - label-retaining cells

KW - tumour-initiating cells

UR - http://www.scopus.com/inward/record.url?scp=79957472391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957472391&partnerID=8YFLogxK

U2 - 10.1093/brain/awr081

DO - 10.1093/brain/awr081

M3 - Article

C2 - 21515906

AN - SCOPUS:79957472391

VL - 134

SP - 1331

EP - 1343

JO - Brain

JF - Brain

SN - 0006-8950

IS - 5

ER -